This was based on the results of the GEOMETRY mono-1 (NCT02414139), a multicenter, non-randomized, open-label, multi-cohort, phase 2 trial evaluating capmatinib (400 mg orally twice daily) in EGFR wild-type and ALK-negative NSCLC patients with MET alterations, including MET exon 14 skipping mutation or MET amplification. This evidence concerns the gene MET and non-small cell lung carcinoma.